Back to Royal Bank of Canada Royal Bank of Canada

CLDXCLDX

Showing 8 of 28 quarters

Position history for Royal Bank of CanadaRoyal Bank of Canada's holdings in Celldex Therapeutics, Inc.

Yes. Royal Bank of Canada holds 2,747 shares of CLDX (Celldex Therapeutics), worth $102,000, as of its Q2 2026 13F filing. It increased the position from 502 shares in Q1 2026. Royal Bank of Canada has held CLDX since Q2 2021, across 21 quarterly 13F filings.

Current Value

$102,000

Current Shares

2,747

Total Value Change

-$161,000

Total Shares Change

-5,006

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
2,747
+447.2%
$102,0000.0%$37.21
24
2026-Q1
Decreased
502
-78.1%
$16,0000.0%$31.72
0
2025-Q4
Decreased
2,292
-95.0%
$62,0000.0%$27.16
0
2025-Q3
Decreased
45,401
-10.3%
$1.2M0.0%$25.87
0
2025-Q2
Increased
50,615
+8874.3%
$1M0.0%$20.35
40
2025-Q1
Decreased
564
-81.4%
$10,0000.0%$18.15
0
2024-Q4
Decreased
3,030
-60.9%
$76,0000.0%$25.27
0
2024-Q3
Increased
7,753
+17.0%
$263,0000.0%$33.99
27

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used